Get Live Data

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Allergy Thera. Share Price
  4. Allergy Thera. Share Regulatory News
  5. Trading Statement

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Allergy Thera. Information

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: -0.13 (-2.42%)
Spread: 0.50 (10.00%)
Open: 5.35
High: 5.38
Low: 5.00
Prev. Close: 5.38
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

14 Jul 2006 07:01

Allergy Therapeutics PLC14 July 2006 Allergy Therapeutics plc, "Allergy Therapeutics" or "the Company" Trading update Allergy Therapeutics plc, the specialist pharmaceuticals company focused onallergy vaccination, today issues the following pre-close trading updaterelating to the financial year ended 30 June 2006. The preliminary results for the year will be announced on 12 September 2006.Sales for the year are expected to be approximately £23.5m, in line with currentmarket expectations. Allergy Therapeutics has made excellent progress with its clinical programmesduring the year. These programmes are focused on the development of theCompany's lead product, Pollinex(R) Quattro, an innovative four-shot vaccinationfor allergy sufferers. Allergy Therapeutics is now in an excellent position, having: - one product ready for submission for registration in Canada - Pollinex Quattro Ragweed - one product in Phase III studies worldwide - Pollinex Quattro Grass o Clarity on the crucially important 'route to registration' established - two products at the Phase II/III interface worldwide - Pollinex Quattro Tree and Pollinex Quattro Ragweed - the financial resources to continue the development programme independently - the clinical results to explore options for partnering from a position of strength -ends- Allergy Therapeutics 01903 844720 Keith Carter, Chief Executive Ian Postlethwaite, Finance Director Bell Pottinger 020 7861 3232 Dan de Belder / Emma Charlton This information is provided by RNS The company news service from the London Stock Exchange
5678910111213
Date   Source Headline
26th Sep 20167:00 amRNSAllergy Therapeutics Preliminary Results
20th Sep 20164:58 pmRNSIssue of equity in respect of exercise of options
5th Sep 20167:00 amRNSNotice of Preliminary Results
13th Jul 20167:00 amRNSTrading Update
8th Jul 20167:00 amRNSResults of mite immunotherapy Acarovac PlusT
27th Jun 20167:00 amRNSFindings from mEEC dose range finding study G204
13th Jun 20167:00 amRNSAllergy hosts Satellite Symposium at EAACI
10th Jun 20167:00 amRNSAppointment of Finance Director
9th May 20167:00 amRNSPositive Phase II Data
23rd Mar 20169:02 amRNSIssue of equity in respect of options exercise
17th Mar 20167:00 amRNSBoard Change
11th Mar 20164:36 pmRNSGrant of Options under Long Term Incentive Plan
8th Mar 20167:00 amRNSInterim Results for the six months ended 31/12/15
24th Feb 20167:30 amRNSHardman & Co Research Report: Development Progress
23rd Feb 20167:00 amRNSNotice of Interim Results
18th Feb 20167:00 amRNSPatient enrolment completed in US Phase IIb study
13th Jan 20167:00 amRNSTrading Update
7th Dec 20157:00 amRNSUS Phase II study for GrassMATAMPL initiated
2nd Dec 20153:47 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSPQBirch204 Phase II study update
27th Nov 20153:21 pmRNSHolding(s) in Company
25th Nov 20156:06 pmRNSGrant of Options under Long Term Incentive Plan
18th Nov 201512:23 pmRNSResult of AGM
17th Nov 201512:51 pmRNSResults of Placing
17th Nov 20157:01 amRNSProposed placing to raise up to £12 million
17th Nov 20157:00 amRNSTrading Update
4th Nov 20157:00 amRNSWorld Vaccine Congress Presentation
21st Oct 20152:48 pmRNSHardman & Co issues research report
16th Oct 20157:00 amRNSAnnual Report and Accounts
21st Sep 20157:00 amRNSFinal Results
1st Sep 20157:04 amRNSFirst patient recruited in PQ Birch dose study
10th Aug 20157:00 amRNSKey paper published in the World Allergy Journal
27th Jul 20157:00 amRNSDirector Share Dealings
23rd Jul 20157:00 amRNSNotice of Results and Trading Update
6th Jul 20157:00 amRNSPositive Dust Mite Study Results
2nd Jul 20157:00 amRNSCompany to Host Key Allergy Conference
25th Jun 20157:00 amRNSCompany to resume US clinical programme
5th Jun 201510:59 amRNSAcquisition of Alerpharma S.A.
9th Apr 20155:51 pmRNSHolding(s) in Company
8th Apr 20153:47 pmRNSHolding(s) in Company
1st Apr 20153:20 pmRNSHolding(s) in Company
30th Mar 201511:27 amRNSResult of General Meeting and Issue of Equity
10th Mar 20157:03 amRNSIssue of Equity
2nd Mar 20157:00 amRNSHalf Yearly Report
30th Jan 20153:58 pmRNSHolding(s) in Company
12th Jan 20157:00 amRNSTrading Update
16th Dec 20142:00 pmRNSChange of Adviser
19th Nov 20141:16 pmRNSResult of AGM
18th Nov 20147:00 amRNSAppointment of a Non-Executive Director
5th Nov 20147:00 amRNSGrant of Options
5678910111213

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.